Cite
HARVARD Citation
Gonzalez-Duarte, A. et al. (n.d.). P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. Canadian journal of neurological sciences. p. S20. [Online].